Overview

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Status:
Terminated

Trial end date:
2007-02-01

Target enrollment:

Participant gender:

Summary

- Primary : To determine the safety profile of each treatment group. - Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Cisplatin
Docetaxel